Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.42, while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | VRTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $529.65 |
52-Week Low | $9.98 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.54, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions, though analyst reports express concerns over potential net asset value erosion despite the high yield strategy.
The outlook is mixed; the high-yield dividend strategy attracts income investors, but fundamental risks include underperformance versus Amazon and sustainability of payouts. Key risks involve amplified downside exposure and competitive pressures, warranting cautious evaluation for long-term growth-oriented investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
